Published in J Virol on April 01, 1987
Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1989) 12.54
Myristoylation-dependent replication and assembly of human immunodeficiency virus 1. Proc Natl Acad Sci U S A (1990) 8.23
Identification of a membrane-binding domain within the amino-terminal region of human immunodeficiency virus type 1 Gag protein which interacts with acidic phospholipids. J Virol (1994) 6.67
The matrix protein of human immunodeficiency virus type 1 is required for incorporation of viral envelope protein into mature virions. J Virol (1992) 5.30
Creation and expression of myristylated forms of Rous sarcoma virus gag protein in mammalian cells. J Virol (1989) 4.60
Single amino acid changes in the human immunodeficiency virus type 1 matrix protein block virus particle production. J Virol (1994) 4.40
Role of the matrix protein in the virion association of the human immunodeficiency virus type 1 envelope glycoprotein. J Virol (1994) 4.28
Suppression of retroviral MA deletions by the amino-terminal membrane-binding domain of p60src. J Virol (1991) 4.25
Mutations in the N-terminal region of human immunodeficiency virus type 1 matrix protein block intracellular transport of the Gag precursor. J Virol (1993) 4.20
Cyclophilin A is required for an early step in the life cycle of human immunodeficiency virus type 1 before the initiation of reverse transcription. J Virol (1996) 4.15
Biochemical and immunological analysis of human immunodeficiency virus gag gene products p17 and p24. J Virol (1988) 4.06
Identification of human immunodeficiency virus type 1 Gag protein domains essential to membrane binding and particle assembly. J Virol (1994) 3.85
A large deletion in the matrix domain of the human immunodeficiency virus gag gene redirects virus particle assembly from the plasma membrane to the endoplasmic reticulum. J Virol (1993) 3.75
Functional chimeras of the Rous sarcoma virus and human immunodeficiency virus gag proteins. J Virol (1993) 3.71
A proline-rich motif (PPPY) in the Gag polyprotein of Mason-Pfizer monkey virus plays a maturation-independent role in virion release. J Virol (1998) 3.69
The GAG precursor of simian immunodeficiency virus assembles into virus-like particles. EMBO J (1989) 3.50
Proteins related to the Nedd4 family of ubiquitin protein ligases interact with the L domain of Rous sarcoma virus and are required for gag budding from cells. Proc Natl Acad Sci U S A (2001) 3.04
Spike protein-nucleocapsid interactions drive the budding of alphaviruses. J Virol (1992) 2.91
Unmyristylated Moloney murine leukemia virus Pr65gag is excluded from virus assembly and maturation events. J Virol (1989) 2.90
Role of the Gag matrix domain in targeting human immunodeficiency virus type 1 assembly. J Virol (2000) 2.85
Human immunodeficiency virus type 1 Gag proteins are processed in two cellular compartments. Proc Natl Acad Sci U S A (1991) 2.80
Overexpression of the gag-pol precursor from human immunodeficiency virus type 1 proviral genomes results in efficient proteolytic processing in the absence of virion production. J Virol (1991) 2.65
Protein N-myristoylation in Escherichia coli: reconstitution of a eukaryotic protein modification in bacteria. Proc Natl Acad Sci U S A (1990) 2.61
Mutational analysis of the major homology region of Mason-Pfizer monkey virus by use of saturation mutagenesis. J Virol (1992) 2.56
Amino acid substitutions within the matrix protein of type D retroviruses affect assembly, transport and membrane association of a capsid. EMBO J (1991) 2.51
Preassembled capsids of type D retroviruses contain a signal sufficient for targeting specifically to the plasma membrane. J Virol (1990) 2.51
The C terminus of human immunodeficiency virus type 1 matrix protein is involved in early steps of the virus life cycle. J Virol (1992) 2.51
Specificity and sequence requirements for interactions between various retroviral Gag proteins. J Virol (1994) 2.50
Conditional infectivity of a human immunodeficiency virus matrix domain deletion mutant. J Virol (1993) 2.42
Myristoylation is important at multiple stages in poliovirus assembly. J Virol (1991) 2.36
Structural role of the matrix protein of type D retroviruses in gag polyprotein stability and capsid assembly. J Virol (1990) 2.34
Role of myristoylation of poliovirus capsid protein VP4 as determined by site-directed mutagenesis of its N-terminal sequence. EMBO J (1989) 2.24
Efficient particle formation can occur if the matrix domain of human immunodeficiency virus type 1 Gag is substituted by a myristylation signal. J Virol (1994) 2.21
Importance of basic residues in the nucleocapsid sequence for retrovirus Gag assembly and complementation rescue. J Virol (1998) 2.18
The nonmyristylated Pr160gag-pol polyprotein of human immunodeficiency virus type 1 interacts with Pr55gag and is incorporated into viruslike particles. J Virol (1992) 2.17
Capsid protein VP4 of poliovirus is N-myristoylated. Proc Natl Acad Sci U S A (1987) 2.12
Mammalian reoviruses contain a myristoylated structural protein. J Virol (1991) 2.09
Novel N-terminal amino acid sequence required for retention of a hepatitis B virus glycoprotein in the endoplasmic reticulum. Mol Cell Biol (1989) 2.05
Conditional lethal expression of the vaccinia virus L1R myristylated protein reveals a role in virion assembly. J Virol (1994) 2.04
Expression and extracellular release of human immunodeficiency virus type 1 Gag precursors by recombinant baculovirus-infected cells. J Virol (1992) 1.89
Synthesis and assembly of retrovirus Gag precursors into immature capsids in vitro. J Virol (1996) 1.85
The roles of Pol and Env in the assembly pathway of human foamy virus. J Virol (1998) 1.82
Efficient in vivo and in vitro assembly of retroviral capsids from Gag precursor proteins expressed in bacteria. J Virol (1995) 1.81
A nucleotide substitution in the gag N terminus of the endogenous ecotropic DBA/2 virus prevents Pr65gag myristylation and virus replication. J Virol (1988) 1.72
N myristoylation of the spleen necrosis virus matrix protein is required for correct association of the Gag polyprotein with intracellular membranes and for particle formation. J Virol (1990) 1.71
Integration target site selection by a resurrected human endogenous retrovirus. Genes Dev (2009) 1.62
Binding of the human immunodeficiency virus type 1 Gag polyprotein to cyclophilin A is mediated by the central region of capsid and requires Gag dimerization. J Virol (1996) 1.59
RNA-binding properties of the matrix protein (p19gag) of avian sarcoma and leukemia viruses. J Virol (1990) 1.59
Characterization of human immunodeficiency virus type 1 Pr55gag membrane association in a cell-free system: requirement for a C-terminal domain. Proc Natl Acad Sci U S A (1994) 1.49
Assembly and processing of avian retroviral gag polyproteins containing linked protease dimers. J Virol (1991) 1.48
Replication of human immunodeficiency virus 1 and Moloney murine leukemia virus is inhibited by different heteroatom-containing analogs of myristic acid. Proc Natl Acad Sci U S A (1989) 1.47
Effect of retroviral proteinase inhibitors on Mason-Pfizer monkey virus maturation and transmembrane glycoprotein cleavage. J Virol (1992) 1.46
Domains upstream of the protease (PR) in human immunodeficiency virus type 1 Gag-Pol influence PR autoprocessing. J Virol (1995) 1.45
A large region within the Rous sarcoma virus matrix protein is dispensable for budding and infectivity. J Virol (1996) 1.43
Lack of myristoylation of poliovirus capsid polypeptide VP0 prevents the formation of virions or results in the assembly of noninfectious virus particles. J Virol (1990) 1.41
Identification of a conserved residue of foamy virus Gag required for intracellular capsid assembly. J Virol (2001) 1.38
Acylation of viral and eukaryotic proteins. Biochem J (1989) 1.38
Heteroatom-substituted fatty acid analogs as substrates for N-myristoyltransferase: an approach for studying both the enzymology and function of protein acylation. Proc Natl Acad Sci U S A (1988) 1.37
Matrix protein of Akv murine leukemia virus: genetic mapping of regions essential for particle formation. J Virol (1992) 1.37
Membrane targeting properties of a herpesvirus tegument protein-retrovirus Gag chimera. J Virol (2000) 1.36
Myristylation of Rous sarcoma virus Gag protein does not prevent replication in avian cells. J Virol (1990) 1.36
Late viral interference induced by transdominant Gag of an endogenous retrovirus. Proc Natl Acad Sci U S A (2004) 1.34
Identification of a cytoplasmic targeting/retention signal in a retroviral Gag polyprotein. J Virol (1999) 1.33
Analysis of gag proteins from mouse mammary tumor virus. J Virol (1989) 1.27
Myristylation of poliovirus capsid precursor P1 is required for assembly of subviral particles. J Virol (1992) 1.25
Basic residues in the Mason-Pfizer monkey virus gag matrix domain regulate intracellular trafficking and capsid-membrane interactions. J Virol (2007) 1.24
Human immunodeficiency virus type 1 MA deletion mutants expressed in baculovirus-infected cells: cis and trans effects on the Gag precursor assembly pathway. J Virol (1995) 1.24
Rapid localization of Gag/GagPol complexes to detergent-resistant membrane during the assembly of human immunodeficiency virus type 1. J Virol (2003) 1.23
Type D retrovirus capsid assembly and release are active events requiring ATP. J Virol (1998) 1.22
Myristoylation of budgerigar fledgling disease virus capsid protein VP2. J Virol (1989) 1.22
Importance of p12 protein in Mason-Pfizer monkey virus assembly and infectivity. J Virol (1992) 1.19
Assembly and composition of intracellular particles formed by Moloney murine leukemia virus. J Virol (1993) 1.19
Altered membrane association of p60v-src and a murine 63-kDa N-myristoyl protein after incorporation of an oxygen-substituted analog of myristic acid. Proc Natl Acad Sci U S A (1989) 1.18
Myristic acid auxotrophy caused by mutation of S. cerevisiae myristoyl-CoA:protein N-myristoyltransferase. J Cell Biol (1991) 1.18
An infectious progenitor for the murine IAP retrotransposon: emergence of an intracellular genetic parasite from an ancient retrovirus. Genome Res (2008) 1.17
Mechanisms of late restriction induced by an endogenous retrovirus. J Virol (2007) 1.17
Link between genome packaging and rate of budding for Rous sarcoma virus. J Virol (2003) 1.15
Type D retrovirus Gag polyprotein interacts with the cytosolic chaperonin TRiC. J Virol (2001) 1.14
Separate assembly and transport domains within the Gag precursor of Mason-Pfizer monkey virus. J Virol (1999) 1.13
Mutations within the env gene of Mason-Pfizer monkey virus: effects on protein transport and SU-TM association. J Virol (1992) 1.12
Murine MusD retrotransposon: structure and molecular evolution of an "intracellularized" retrovirus. J Virol (2006) 1.07
Plasma membrane targeting of chimeric intracisternal A-type particle polyproteins leads to particle release and specific activation of the viral proteinase. J Virol (1997) 1.05
Mutagenesis of the 43-kD postsynaptic protein defines domains involved in plasma membrane targeting and AChR clustering. J Cell Biol (1991) 1.05
Murine leukemia virus particle assembly quantitated by fluorescence microscopy: role of Gag-Gag interactions and membrane association. J Virol (2003) 1.05
Use of a cell-free system to identify the vaccinia virus L1R gene product as the major late myristylated virion protein M25. J Virol (1990) 1.05
Multiple functions for the basic amino acids of the human T-cell leukemia virus type 1 matrix protein in viral transmission. J Virol (1999) 1.03
Fatty acid acylation of vaccinia virus proteins. J Virol (1989) 1.03
Variable sensitivity to substitutions in the N-terminal heptad repeat of Mason-Pfizer monkey virus transmembrane protein. J Virol (2003) 1.02
Functional analysis of protein N-myristoylation: metabolic labeling studies using three oxygen-substituted analogs of myristic acid and cultured mammalian cells provide evidence for protein-sequence-specific incorporation and analog-specific redistribution. Proc Natl Acad Sci U S A (1990) 1.02
Mutations in the amino terminus of foamy virus Gag disrupt morphology and infectivity but do not target assembly. J Virol (2008) 1.00
A tyrosine motif in the cytoplasmic domain of mason-pfizer monkey virus is essential for the incorporation of glycoprotein into virions. J Virol (2003) 0.99
D-retrovirus morphogenetic switch driven by the targeting signal accessibility to Tctex-1 of dynein. Proc Natl Acad Sci U S A (2008) 0.97
Retroviral matrix and lipids, the intimate interaction. Retrovirology (2011) 0.96
N myristylation of the human immunodeficiency virus type 1 gag polyprotein precursor in Saccharomyces cerevisiae. J Virol (1989) 0.96
Acetylcholine receptor-associated 43K protein contains covalently bound myristate. J Cell Biol (1988) 0.95
Activation of the Mason-Pfizer monkey virus protease within immature capsids in vitro. Proc Natl Acad Sci U S A (2001) 0.95
A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology (1973) 127.36
THE PREPARATION OF I-131-LABELLED HUMAN GROWTH HORMONE OF HIGH SPECIFIC RADIOACTIVITY. Biochem J (1963) 61.56
Transfer of proteins across membranes. I. Presence of proteolytically processed and unprocessed nascent immunoglobulin light chains on membrane-bound ribosomes of murine myeloma. J Cell Biol (1975) 36.95
Intracellular aspects of the process of protein synthesis. Science (1975) 25.21
A short amino acid sequence able to specify nuclear location. Cell (1984) 21.17
Oligonucleotide-directed mutagenesis: a simple method using two oligonucleotide primers and a single-stranded DNA template. DNA (1984) 14.55
Intracellular protein topogenesis. Proc Natl Acad Sci U S A (1980) 13.40
Sequence requirements for nuclear location of simian virus 40 large-T antigen. Nature (1984) 10.52
Mechanisms for the incorporation of proteins in membranes and organelles. J Cell Biol (1982) 9.67
An improved technique for obtaining enhanced infectivity with herpes simplex virus type 1 DNA. J Gen Virol (1976) 8.07
A short sequence in the p60src N terminus is required for p60src myristylation and membrane association and for cell transformation. Mol Cell Biol (1984) 6.40
Nucleotide sequence of Mason-Pfizer monkey virus: an immunosuppressive D-type retrovirus. Cell (1986) 6.07
A deletion mutation in the 5' part of the pol gene of Moloney murine leukemia virus blocks proteolytic processing of the gag and pol polyproteins. J Virol (1985) 5.78
Myristyl amino-terminal acylation of murine retrovirus proteins: an unusual post-translational proteins modification. Proc Natl Acad Sci U S A (1983) 5.12
n-Tetradecanoyl is the NH2-terminal blocking group of the catalytic subunit of cyclic AMP-dependent protein kinase from bovine cardiac muscle. Proc Natl Acad Sci U S A (1982) 4.51
In vivo modification of retroviral gag gene-encoded polyproteins by myristic acid. J Virol (1983) 4.09
An N-terminal peptide from p60src can direct myristylation and plasma membrane localization when fused to heterologous proteins. Nature (1985) 4.06
An electron microscopic study of moderate and virulent virus-cell interactions of the parainfluenza virus SV5. Virology (1966) 4.03
Amino terminal myristylation of the protein kinase p60src, a retroviral transforming protein. Science (1985) 3.97
Fatty acid binding to vesicular stomatitis virus glycoprotein: a new type of post-translational modification of the viral glycoprotein. Cell (1979) 3.87
Myristic acid, a rare fatty acid, is the lipid attached to the transforming protein of Rous sarcoma virus and its cellular homolog. J Virol (1985) 3.47
Evidence for covalent attachment of fatty acids to Sindbis virus glycoproteins. Proc Natl Acad Sci U S A (1979) 3.46
Identification of the NH2-terminal blocking group of calcineurin B as myristic acid. FEBS Lett (1982) 3.42
A new virus in a spontaneous mammary tumor of a rhesus monkey. Cancer Res (1970) 3.02
Myristic acid is attached to the transforming protein of Rous sarcoma virus during or immediately after synthesis and is present in both soluble and membrane-bound forms of the protein. Mol Cell Biol (1984) 2.98
A 70-kd protein of the yeast mitochondrial outer membrane is targeted and anchored via its extreme amino terminus. EMBO J (1984) 2.96
Rous sarcoma virus transforming protein lacking myristic acid phosphorylates known polypeptide substrates without inducing transformation. Cell (1986) 2.84
The absence of myristic acid decreases membrane binding of p60src but does not affect tyrosine protein kinase activity. J Virol (1986) 2.59
Fine structural mapping of a critical NH2-terminal region of p60src. Proc Natl Acad Sci U S A (1985) 2.53
Interaction between the Rous sarcoma virus transforming protein and two cellular phosphoproteins: analysis of the turnover and distribution of this complex. Mol Cell Biol (1983) 2.46
DNA sequence of the viral and cellular src gene of chickens. II. Comparison of the src genes of two strains of avian sarcoma virus and of the cellular homolog. J Virol (1982) 2.46
Purification and N-terminal amino acid sequence comparisons of structural proteins from retrovirus-D/Washington and Mason-Pfizer monkey virus. J Virol (1985) 2.43
Processing of p60v-src to its myristylated membrane-bound form. Mol Cell Biol (1985) 2.41
Only membrane-associated RSV src proteins have amino-terminally bound lipid. Nature (1983) 2.37
Transit of pp60v-src to the plasma membrane. Proc Natl Acad Sci U S A (1982) 2.29
Infection of eucaryotic cells by helper-independent recombinant adenoviruses: early region 1 is not obligatory for integration of viral DNA. J Virol (1984) 2.28
Myristylation of gag-onc fusion proteins in mammalian transforming retroviruses. Virology (1984) 2.22
Identification of the NH2-terminal blocking group of NADH-cytochrome b5 reductase as myristic acid and the complete amino acid sequence of the membrane-binding domain. J Biol Chem (1984) 2.14
The use of nuclear-encoded sequences to direct the light-regulated synthesis and transport of a foreign protein into plant chloroplasts. EMBO J (1985) 1.99
Characterization of the protein apparently responsible for the elevated tyrosine protein kinase activity in LSTRA cells. Mol Cell Biol (1984) 1.92
Polypeptides of Mason-Pfizer monkey virus. I. Synthesis and processing of the gag-gene products. Virology (1984) 1.83
Ultrastructural comparison of a virus from a Rhesus-monkey mammary carcinoma with four oncogenic RNA viruses. Proc Natl Acad Sci U S A (1971) 1.67
Intracellular transport of herpes simplex virus gD occurs more rapidly in uninfected cells than in infected cells. J Virol (1985) 1.56
Avian sarcoma virus gag precursor polypeptide is not processed in mammalian cells. J Virol (1982) 1.46
Responses of infant rhesus monkeys to inoculation with Mason-Pfizer monkey virus materials. J Natl Cancer Inst (1975) 1.44
Effect of cloned human interferons on protein synthesis and morphogenesis of herpes simplex virus. J Virol (1985) 1.38
A rapid screening procedure for the isolation of nonconditional replication mutants of Mason-Pfizer monkey virus: identification of a mutant defective in pol. Virology (1985) 1.19
Evidence for a precursor-product relationship between intracytoplasmic A particles and mouse mammary tumour virus cores. J Gen Virol (1978) 1.10
Polypeptides of Mason-Pfizer monkey virus. II. Synthesis and processing of the env gene products. Virology (1986) 1.09
Molecular cloning of the Mason-Pfizer monkey virus genome: characterization and cloning of subgenomic fragments. Virology (1985) 1.08
Nonconditional replication mutants of type C and type D retroviruses defective in gag gene-coded polyprotein post-translational processing. Virology (1978) 1.06
Polypeptides of Mason-Pfizer monkey virus. III. Translational order of proteins on the gag and env gene specified precursor polypeptides. Virology (1986) 1.03
Effect of monensin on Mason-Pfizer monkey virus glycoprotein synthesis. J Virol (1982) 1.02
Morphological and biophysical properties of the Mason-Pfizer monkey virus. J Natl Cancer Inst (1972) 0.95
The characterization of Mason-Pfizer monkey virus-induced cell fusion. Virology (1979) 0.94
Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med (1998) 8.62
Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol (2000) 6.71
Nucleotide sequence of Mason-Pfizer monkey virus: an immunosuppressive D-type retrovirus. Cell (1986) 6.07
A small element from the Mason-Pfizer monkey virus genome makes human immunodeficiency virus type 1 expression and replication Rev-independent. Proc Natl Acad Sci U S A (1994) 4.43
Truncation of the human immunodeficiency virus type 1 transmembrane glycoprotein cytoplasmic domain blocks virus infectivity. J Virol (1992) 4.20
A single amino acid substitution within the matrix protein of a type D retrovirus converts its morphogenesis to that of a type C retrovirus. Cell (1990) 3.70
A proline-rich motif (PPPY) in the Gag polyprotein of Mason-Pfizer monkey virus plays a maturation-independent role in virion release. J Virol (1998) 3.69
Mutations in the leucine zipper of the human immunodeficiency virus type 1 transmembrane glycoprotein affect fusion and infectivity. J Virol (1992) 3.54
Mutants of the Rous sarcoma virus envelope glycoprotein that lack the transmembrane anchor and cytoplasmic domains: analysis of intracellular transport and assembly into virions. J Virol (1987) 3.28
Human immunodeficiency virus envelope protein determines the site of virus release in polarized epithelial cells. Proc Natl Acad Sci U S A (1991) 3.18
Mutations of the Rous sarcoma virus env gene that affect the transport and subcellular location of the glycoprotein products. J Cell Biol (1984) 3.11
Oligomeric structure of a prototype retrovirus glycoprotein. Proc Natl Acad Sci U S A (1988) 3.06
Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex. Proc Natl Acad Sci U S A (1994) 2.88
Mutational analysis of the major homology region of Mason-Pfizer monkey virus by use of saturation mutagenesis. J Virol (1992) 2.56
Complete sequence of the Rous sarcoma virus env gene: identification of structural and functional regions of its product. J Virol (1983) 2.53
Preassembled capsids of type D retroviruses contain a signal sufficient for targeting specifically to the plasma membrane. J Virol (1990) 2.51
Amino acid substitutions within the matrix protein of type D retroviruses affect assembly, transport and membrane association of a capsid. EMBO J (1991) 2.51
Amino acids encoded downstream of gag are not required by Rous sarcoma virus protease during gag-mediated assembly. J Virol (1991) 2.38
Structural role of the matrix protein of type D retroviruses in gag polyprotein stability and capsid assembly. J Virol (1990) 2.34
Functional RT and IN incorporated into HIV-1 particles independently of the Gag/Pol precursor protein. EMBO J (1997) 2.23
Mutations within the proteolytic cleavage site of the Rous sarcoma virus glycoprotein that block processing to gp85 and gp37. J Virol (1987) 2.07
Truncations of the simian immunodeficiency virus transmembrane protein confer expanded virus host range by removing a block to virus entry into cells. J Virol (1993) 1.99
Postassembly cleavage of a retroviral glycoprotein cytoplasmic domain removes a necessary incorporation signal and activates fusion activity. J Virol (1994) 1.97
Role of the membrane-proximal domain in the initial stages of human immunodeficiency virus type 1 envelope glycoprotein-mediated membrane fusion. J Virol (1999) 1.89
Synthesis and assembly of retrovirus Gag precursors into immature capsids in vitro. J Virol (1996) 1.85
Polypeptides of Mason-Pfizer monkey virus. I. Synthesis and processing of the gag-gene products. Virology (1984) 1.83
A viral protease-mediated cleavage of the transmembrane glycoprotein of Mason-Pfizer monkey virus can be suppressed by mutations within the matrix protein. Proc Natl Acad Sci U S A (1992) 1.83
Efficient in vivo and in vitro assembly of retroviral capsids from Gag precursor proteins expressed in bacteria. J Virol (1995) 1.81
A chimeric avian retrovirus containing the influenza virus hemagglutinin gene has an expanded host range. J Virol (1992) 1.80
Distinct subsets of retroviruses encode dUTPase. J Virol (1992) 1.80
Avian reticuloendotheliosis viruses: evolutionary linkage with mammalian type C retroviruses. J Virol (1979) 1.68
The mechanism for genetic recombination in the avian retroviruses. Curr Top Microbiol Immunol (1978) 1.67
Biological techniques for avian sarcoma viruses. Methods Enzymol (1979) 1.67
Analysis of the cleavage site of the human immunodeficiency virus type 1 glycoprotein: requirement of precursor cleavage for glycoprotein incorporation. J Virol (1995) 1.54
A charged amino acid substitution within the transmembrane anchor of the Rous sarcoma virus envelope glycoprotein affects surface expression but not intracellular transport. J Cell Biol (1987) 1.50
Mutations within the proteolytic cleavage site of the Rous sarcoma virus glycoprotein define a requirement for dibasic residues for intracellular cleavage. J Virol (1992) 1.50
Expression and characterization of glycophospholipid-anchored human immunodeficiency virus type 1 envelope glycoproteins. J Virol (1993) 1.47
Effect of retroviral proteinase inhibitors on Mason-Pfizer monkey virus maturation and transmembrane glycoprotein cleavage. J Virol (1992) 1.46
Amino-terminal amino acid sequence of the major structural polypeptides of avian retroviruses: sequence homology between reticuloendotheliosis virus p30 and p30s of mammalian retroviruses. Proc Natl Acad Sci U S A (1978) 1.46
AIDS biosafety. Science (1991) 1.44
Pausing of reverse transcriptase on retroviral RNA templates is influenced by secondary structures both 5' and 3' of the catalytic site. Nucleic Acids Res (1998) 1.43
Inhibition of Rous sarcoma virus replication by 2-deoxyglucose and tunicamycin: identification of an unglycosylated env gene product. J Virol (1979) 1.42
Oligomerization of the hydrophobic heptad repeat of gp41. J Virol (1995) 1.38
Functional analysis of the core human immunodeficiency virus type 1 packaging signal in a permissive cell line. J Virol (1998) 1.38
Effect of cloned human interferons on protein synthesis and morphogenesis of herpes simplex virus. J Virol (1985) 1.38
Human immunodeficiency virus type 1 envelope glycoprotein is modified by O-linked oligosaccharides. J Virol (1994) 1.35
V3 loop region of the HIV-1 gp120 envelope protein is essential for virus infectivity. Virology (1992) 1.35
Identification of a cytoplasmic targeting/retention signal in a retroviral Gag polyprotein. J Virol (1999) 1.33
An avian sarcoma virus mutant that is temperature sensitive for virion assembly. Virology (1976) 1.33
Alterations in the transport and processing of Rous sarcoma virus envelope glycoproteins mutated in the signal and anchor regions. J Cell Biochem (1983) 1.31
Type D retrovirus capsid assembly and release are active events requiring ATP. J Virol (1998) 1.22
Amino-terminal deletion mutants of the Rous sarcoma virus glycoprotein do not block signal peptide cleavage but can block intracellular transport. J Cell Biol (1986) 1.21
Mutational analysis of conserved domains within the cytoplasmic tail of gp41 from human immunodeficiency virus type 1: effects on glycoprotein incorporation and infectivity. J Virol (2000) 1.21
Molecular cloning of the wild-type phoM operon in Escherichia coli K-12. J Bacteriol (1988) 1.20
A rapid screening procedure for the isolation of nonconditional replication mutants of Mason-Pfizer monkey virus: identification of a mutant defective in pol. Virology (1985) 1.19
Importance of p12 protein in Mason-Pfizer monkey virus assembly and infectivity. J Virol (1992) 1.19
Expression of the Rous sarcoma virus env gene from a simian virus 40 late-region replacement vector: effects of upstream initiation codons. J Virol (1987) 1.18
Alignment of the peptides derived from acid-catalyzed cleavage of an aspartylprolyl bond in the major internal structural polypeptide of avian retroviruses. J Biol Chem (1980) 1.17
Molecular events in the assembly of retrovirus particles. Adv Exp Med Biol (1998) 1.16
T lymphocyte cytotoxicity with natural varicella-zoster virus infection and after immunization with live attenuated varicella vaccine. J Immunol (1989) 1.15
Type D retrovirus Gag polyprotein interacts with the cytosolic chaperonin TRiC. J Virol (2001) 1.14
Separate assembly and transport domains within the Gag precursor of Mason-Pfizer monkey virus. J Virol (1999) 1.13
Can otolith elemental chemistry retrospectively track migrations in fully marine fishes? J Fish Biol (2012) 1.12
Mutations within the env gene of Mason-Pfizer monkey virus: effects on protein transport and SU-TM association. J Virol (1992) 1.12
Immunodeficiency in rhesus monkeys associated with the original Mason-Pfizer monkey virus. J Natl Cancer Inst (1986) 1.11
Health-related behaviours as predictors of mortality and morbidity in Australian Aborigines. Prev Med (2006) 1.09
Palmitoylation of the Rous sarcoma virus transmembrane glycoprotein is required for protein stability and virus infectivity. J Virol (2001) 1.09
Secondary structure model of the Mason-Pfizer monkey virus 5' leader sequence: identification of a structural motif common to a variety of retroviruses. J Virol (1995) 1.09
Polypeptides of Mason-Pfizer monkey virus. II. Synthesis and processing of the env gene products. Virology (1986) 1.09
Production and purification of a recombinant elastomeric polypeptide, G-(VPGVG)19-VPGV, from Escherichia coli. Biotechnol Prog (1992) 1.08
Inhibition of avian sarcoma virus replication by glucosamine. Virology (1974) 1.08
Molecular cloning of the Mason-Pfizer monkey virus genome: characterization and cloning of subgenomic fragments. Virology (1985) 1.08
Analysis of Mason-Pfizer monkey virus Gag particles by scanning transmission electron microscopy. J Virol (2001) 1.07
Interferon inhibits Sendai virus-induced cell fusion: an effect on cell membrane fluidity. Proc Natl Acad Sci U S A (1982) 1.07
Social-cultural aspects of epilepsy in Kilimanjaro Region, Tanzania: knowledge and experience among patients and carers. Epilepsy Behav (2011) 1.07
Transport of membrane proteins to the cell surface. Curr Top Microbiol Immunol (1991) 1.06
Analysis of retroviral assembly using a vaccinia/T7-polymerase complementation system. Virology (1993) 1.06
Analysis of Mason-Pfizer monkey virus Gag domains required for capsid assembly in bacteria: role of the N-terminal proline residue of CA in directing particle shape. J Virol (2000) 1.06
Retention of the human immunodeficiency virus type 1 envelope glycoprotein in the endoplasmic reticulum does not redirect virus assembly from the plasma membrane. J Virol (1998) 1.05
Amino-terminal amino acid sequence of p10, the fifth major gag polypeptide of avian sarcoma and leukemia viruses. J Virol (1983) 1.04
Polypeptides of Mason-Pfizer monkey virus. III. Translational order of proteins on the gag and env gene specified precursor polypeptides. Virology (1986) 1.03
Effect of monensin on Mason-Pfizer monkey virus glycoprotein synthesis. J Virol (1982) 1.02
Three active forms of aspartic proteinase from Mason-Pfizer monkey virus. Virology (1998) 1.01
Mutations within the transmembrane glycoprotein of Mason-Pfizer monkey virus: loss of SU-TM association and effects on infectivity. Virology (1994) 1.01
Inhibition of avian sarcoma virus replication by glucosamine: a specific effect on the synthesis and processing of viral proteins. Virology (1976) 1.00
Calmodulin and HIV type 1: interactions with Gag and Gag products. AIDS Res Hum Retroviruses (2000) 1.00
Integration of ambulance staff trained in cardiopulmonary resuscitation with a medical team providing prehospital coronary care. Br Heart J (1989) 0.99
Haemoglobin sydney: Beta-67 (E11) valine modified to alanine: an emerging pattern of unstable haemoglobins. Nature (1967) 0.98